The rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) market in the three major markets (3MM), namely the US, Germany and Japan. These therapies are projected to capture over 90% of the GHD market share by 2030, according to GlobalData’s recent ‘Growth Hormone Deficiency: Opportunity Assessment and Forecast to 2030’ report. The current leading GH therapeutics such as Novo Nordisk’s Norditropin (somatropin), Pfizer’s Genotropin (somatropin) and Eli Lilly’s Humatrope (somatropin) are likely to see their revenues plummet as a result.

GHD is a rare endocrine disorder characterised by inadequate secretion of GH from the anterior pituitary gland. In 2020, there were 135,098 people diagnosed with GHD across the 3MM, according to GlobalData.

GH replacement therapy using recombinant human (rh) GH currently represents the first-line and only treatment option for this condition, which can affect both children and adults. In children, GH replacement therapy is administered in order to promote normal linear growth and development while in adults it is used to normalise metabolism and body composition.

Short-acting GHs that require patients to self-inject on a daily basis have remained the standard of care in GHD for decades. Norditropin, the current market leader, first entered the market in the 1980s. However, based on primary research with key opinion leaders, GlobalData anticipates that the use of short-acting GHs will be decreased over the forecast period, as almost all patients will switch to treatment with long-acting GHs, which only require patients to self-inject on a weekly basis.

Novo Nordisk’s Sogroya (somapacitan-beco) recently became the first long-acting GH to gain marketing authorisation in GHD for the treatment of adult patients in the US in 2020 and in the EU and Japan in 2021. Additionally, there are three more long-acting GHs in late-stage development (Phase II development or later), according to GlobalData’s pipeline products database, namely Ascendis Pharma’s TransCon hGH (lonapegsomatropin), Pfizer and OPKO Biologics’ somatrogon and Hanmi Pharmaceuticals’ efpegsomatropin.

GlobalData anticipates strong uptake of long-acting GHs, as these therapies have the potential to address key unmet needs for improved patient convenience and compliance. Due to the chronic nature of GHD, patients may have to self-inject for years or even decades. This heavy treatment burden often leads to poor treatment compliance and consequently suboptimal therapeutic outcomes. By dramatically reducing the injection burden for patients, long-acting GHs may improve compliance considerably.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

View profiles in store

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Submit

UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Submit and download

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Across the 3MM, the GHD market was valued at $1.08bn in 2020, approximately 71% of which was attributable to US sales. The market is projected to grow at a compound annual growth rate of 3.84% to reach $1.57bn by 2030. The uptake of long-acting GHs represents the main driver of this growth. These drugs are expected to be priced at a premium to the currently marketed products due to their superior dosing regimens. Furthermore, companies launching long-acting GHs have an opportunity to promote better awareness and understanding of GHD among health care providers, patients and the public, which could lead to improved diagnosis and treatment rates.